Subcutaneous semaglutide: Phase IIIa data

Top-line data from the double-blind, international Phase IIIa SUSTAIN 6 trial in about 3,300 Type II diabetics showed that once-weekly subcutaneous semaglutide plus standard of care

Read the full 264 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE